Gland Pharma Limited has informed the Exchange regarding Resignation of Mr Shyamakant Giri as Chief Executive Officer of the company w.e.f. April 30, 2026.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma Limited has announced the resignation of Mr. Shyamakant Giri as its Chief Executive Officer and Key Managerial Personnel, effective from the close of business hours on April 30, 2026. Mr. Giri submitted his resignation letter dated February 24, 2026, citing his desire to pursue new opportunities, and the Board of Directors accepted it on March 3, 2026 upon the recommendation of the Nomination and Remuneration Committee. The Board has recorded its appreciation for his leadership and contributions during his tenure. Mr. Giri has committed to ensuring a smooth handover of responsibilities. No successor has been named in this announcement.
This is a senior leadership change at a major pharma company. Investors may react with caution until a successor is announced, as CEO transitions can create short-term uncertainty around strategy and execution, though the two-month transition period and Mr. Giri's commitment to a smooth handover help reduce immediate disruption risk.